AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Allergan Announces FDA Approval of ACULAR LS Ophthalmic Solution; The New Formulation of the #1 Prescribed Ophthalmic NSAID in the United States.

Business Wire

| June 02, 2003 | COPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

Business Editors/Health/Medical Writers

IRVINE, Calif.--(BUSINESS WIRE)--June 2, 2003

Allergan, Inc. (NYSE:AGN) today announced the United States Food and Drug Administration (FDA) has approved ACULAR LS(TM) (ketorolac tromethamine ophthalmic solution) 0.4% for the reduction of ocular pain and burning/stinging following corneal refractive surgery.

ACULAR LS(TM) is a new, optimized formulation of ketorolac tromethamine and joins this family of products used for a range of other conditions including post-surgical inflammation, pain, photophobia and ocular itch associated with seasonal allergies. ACULAR LS(TM) will be available in a convenient multi-dose bottle and is currently expected to launch in the third quarter of this year.

In clinical studies, ACULAR LS(TM) significantly reduced pain, burning and stinging following corneal refractive surgery. The most frequently reported adverse reactions for ACULAR LS(TM) ophthalmic solution, occurring in approximately 1 to 5% of the overall study population, were ocular redness, swelling and pain, corneal infiltrates and headache.

Forward-Looking Statements

This press release contains "forward-looking statements," such as statements regarding ACULAR LS(TM) ophthalmic solution, potential growth rates, adverse effects and availability of this product. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and pharmaceutical ...

Related articles from newspapers, magazines, journals, and more
Allergan announces FDA approval of Acular LS ophthalmic solution; the new...
News wire article from: Asia Africa Intelligence Wire June 2, 2003 700+ words
...Press Release) Allergan Inc announced the...FDA) has approved Acular LS (ketorolac tromethamine...ketorolac tromethamine. Acular LS will be available...clinical studies, Acular LS significantly reduced...refractive surgery. Allergan Inc, with headquarters...
New ACULAR LS[R].(Ophthalmic Product Guide: SPECIAL ADVERTISING SECTION)
Magazine article from: Review of Optometry February 15, 2004 700+ words
New ACULAR LS[R] (ketorolac tromethamine...corneal refractive surgery. ACULAR LS is available in a convenient...reported adverse events for ACULAR LS[R] ophthalmic solution...OMITTED] Circle No. 89 Allergan * (800) 377-7790 www...
Acular LS. (In the News).(drug approval)(Brief Article)
Magazine article from: Review of Optometry June 15, 2003 700+ words
The FDA approved Acular LS (ketorolac tromethamine, Allergan) for the reduction of ocular pain, burning or stinging following corneal refractive surgery. Acular LS is a new formulation of ketorolac tromethamine, already...
Allergan and Inspire Enter into Collaboration to Co-Promote Elestat in the U.S.
Press release article from: Business Wire December 8, 2003 700+ words
...early 2004. David Pyott, Allergan's Chairman, President and...Officer said: "With four new Allergan Eye Care products approved...for Elestat(TM) will allow Allergan to focus its sales and marketing...ophthalmic solution 0.3%), and Acular LS(R) (ketorolac tromethamine...
Allergan Reports Third Quarter Operating Results.
Press release article from: Business Wire October 22, 2003 700+ words
...deep pipeline and positioning Allergan as a premier technology driven...the third quarter of 2003: -- Allergan launched Acular LS(TM) (Ketorolac Tromethamine...corneal refractive surgery. -- Allergan received a positive opinion in...
Q3 2005 Allergan Earnings Conference Call - Part 1.
News wire article from: The America's Intelligence Wire November 1, 2005 700+ words
...made by others with respect to Allergan's progress during the quarter cannot be attributed to Allergan. We have provided additional...CHAIRMAN, PRESIDENT, AND CEO, ALLERGAN: Thank you, Jim. Good morning...led by REFRESH, TAZORAC, ACULAR LS and ZYMAR. Regarding income...
Event Brief of Q1 2004 Allergan Earnings Conference Call - Part 1.
News wire article from: The America's Intelligence Wire April 30, 2004 700+ words
...President, CEO . Les Kaplan, Allergan, Inc., President, R&D . Eric Brandt, Allergan, Inc., EVP, Finance...market expanding 9%. 9. Allergan gained market share in...reimbursement in Spain. 3. Acular LS share of the anti-inflammatory...
Event Brief of Q3 2005 Allergan Earnings Conference Call - Part 1.
News wire article from: The America's Intelligence Wire November 1, 2005 700+ words
...and CEO . Jeff Edwards, Allergan, EVP, Finance and Business...Analyst . Scott Whitcup, Allergan, EVP, R&D . Marc...Analyst . Joann Bradley, Allergan, IR OVERVIEW The Co. reported...led by Refresh, Tazorac, Acular LS, and Zymar. 5. AGN enjoyed...
Event Brief of Q3 2005 Allergan Earnings Conference Call - Final.
News wire article from: Fair Disclosure Wire November 1, 2005 700+ words
...and CEO . Jeff Edwards, Allergan, EVP, Finance and Business...Analyst . Scott Whitcup, Allergan, EVP, R&D . Marc...Analyst . Joann Bradley, Allergan, IR OVERVIEW The Co. reported...led by Refresh, Tazorac, Acular LS, and Zymar. 5. AGN enjoyed...
Event Brief of Q3 2003 Allergan Earnings Conference Call - Final.
News wire article from: Fair Disclosure Wire October 22, 2003 700+ words
...amp; CEO . Eric Brandt, Allergan Inc., Corporate VP & CFO . Les Kaplan, Allergan Inc., Corporate VP...Botox . Joann Bradley, Allergan Inc., Speaker OVERVIEW...filings on schedule. 1. Acular LS was launched in the US...
For more facts and information, see all results

Source: HighBeam Research, Allergan Announces FDA Approval of ACULAR LS Ophthalmic Solution; The...

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA